Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone as Adjunctive Therapy to Ranibizumab in CNV and AMD
NCT01122511Phase 2Terminated
- Sponsor
- Allergan
- Start
- Aug 2010
- Primary completion
- May 2011
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dexamethasone in choroidal neovascularization (CNV) and age-related macular degeneration (AMD) (2 arms), sponsored by Allergan. Primary endpoint: Change From Baseline in Best Corrected Visual Acuity at 12 months. Started Aug 2010; status: terminated.
02
Drugs
dexamethasone
03
Conditions
choroidal neovascularization (CNV)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT01122511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01122511.